Skip to main content

Table 2 Summary of adverse events in dupilumab treatment arm

From: Efficacy and safety of dupilumab for the treatment of uncontrolled asthma: a meta-analysis of randomized clinical trials

Event Wenzel 2013 [27] Wenzel 2016 [15] Castro 2018 [26] Rabe 2018 [25] Weinstein 2018 [24]
Any adverse event 42(80.8) 483(79.1) 1023(81.0) 64 (62.1) 195 (78.3)
Serious adverse event 1 (2.0) 45 (7.4) 104 (8.2) 9 (8.7) 15 (6.0)
Any adverse event leading to death NM 2(<0.1) 5 (0.4) 0 0
Study discontinuation owing to treatment-emergent adverse event 3 (5.8) 27 (4.4) 63 (5.0) 1 (1.0) 8 (3.0)
Most common adverse events
 Injection-site reactions 15 (28.8) 79 (12.9) 212 (16.8) 9 (8.7) 60 (24.1)
 Upper respiratory tract infection 7 (13.5) 216 (35.4) 146 (11.6) NM NM
 Viral upper respiratory tract infection 3 (5.8) 83 (13.6) 230 (18.2) 9 (8.7) NM
 Headache 6 (11.5) 62 (10.1) 86 (6.8) NM NM
 Nasopharyngitis 7 (13.5) 59 (9.7) NM NM NM
 Bronchitis NM 51 (8.3) 144 (11.4) 7 (6.8) NM
 Sinusitis 1 (2.0) 36 (5.9) 62 (4.9) 7 (6.8) NM
  1. Note: Data are n (%)
  2. Abbreviations: NM not mentioned